Allison P Pack1, Carol E Golin2, Lauren M Hill3, Jessica Carda-Auten4, Deshira D Wallace4, Sruthi Cherkur4, Claire E Farel5, Elias P Rosen6, Monica Gandhi7, Heather M Asher Prince5, Angela D M Kashuba6. 1. Gillings School of Global Public Health, University of North Carolina at Chapel Hill, United States. Electronic address: apack15@email.unc.edu. 2. Gillings School of Global Public Health, University of North Carolina at Chapel Hill, United States; School of Medicine, University of North Carolina at Chapel Hill, United States; Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, United States. 3. Gillings School of Global Public Health, University of North Carolina at Chapel Hill, United States; Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, United States. 4. Gillings School of Global Public Health, University of North Carolina at Chapel Hill, United States. 5. School of Medicine, University of North Carolina at Chapel Hill, United States. 6. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, United States. 7. School of Medicine, University of California, San Francisco, United States.
Abstract
OBJECTIVE: New pharmacological measures assessing medication adherence, including longitudinal drug levels in hair, are emerging. Little is known, however, about how best to present results from such measures to patients and clinicians in comprehensive, easy-to-understand, acceptable formats. We, therefore, developed three graphical display prototypes of hypothetical daily drug concentrations measured in hair, and assessed their acceptability among participants. METHODS: We interviewed 30 HIV-positive patients and 29 clinicians to examine perceived acceptability for each graphical display prototype. RESULTS: Patients and clinicians generally found the prototypes acceptable for facilitating understanding of patient adherence; however, areas for optimization were identified. For patients with lower health literacy, prototypes did not provide sufficient understanding of the link between medication-taking and drug concentrations in hair. These patients also preferred pictographs over bar or line graphs. Clinicians largely preferred daily drug concentration data in bar graphs with information included about the measure's accuracy. Participants questioned the utility of showing drug concentrations above a therapeutic range, though they found color-coding results acceptable. CONCLUSIONS: Assessing prototype versions of graphical displays of hypothetical longitudinal adherence data indicated ways to optimize their acceptability. PRACTICE IMPLICATIONS: Acceptable prototype-tested graphical displays of longitudinal patient-specific drug concentrations may enhance adherence monitoring in clinical settings.
OBJECTIVE: New pharmacological measures assessing medication adherence, including longitudinal drug levels in hair, are emerging. Little is known, however, about how best to present results from such measures to patients and clinicians in comprehensive, easy-to-understand, acceptable formats. We, therefore, developed three graphical display prototypes of hypothetical daily drug concentrations measured in hair, and assessed their acceptability among participants. METHODS: We interviewed 30 HIV-positive patients and 29 clinicians to examine perceived acceptability for each graphical display prototype. RESULTS:Patients and clinicians generally found the prototypes acceptable for facilitating understanding of patient adherence; however, areas for optimization were identified. For patients with lower health literacy, prototypes did not provide sufficient understanding of the link between medication-taking and drug concentrations in hair. These patients also preferred pictographs over bar or line graphs. Clinicians largely preferred daily drug concentration data in bar graphs with information included about the measure's accuracy. Participants questioned the utility of showing drug concentrations above a therapeutic range, though they found color-coding results acceptable. CONCLUSIONS: Assessing prototype versions of graphical displays of hypothetical longitudinal adherence data indicated ways to optimize their acceptability. PRACTICE IMPLICATIONS: Acceptable prototype-tested graphical displays of longitudinal patient-specific drug concentrations may enhance adherence monitoring in clinical settings.
Authors: Barry D Weiss; Mary Z Mays; William Martz; Kelley Merriam Castro; Darren A DeWalt; Michael P Pignone; Joy Mockbee; Frank A Hale Journal: Ann Fam Med Date: 2005 Nov-Dec Impact factor: 5.166
Authors: Seth C Kalichman; Christina M Amaral; Connie Swetzes; Michelle Jones; Rene Macy; Moira O Kalichman; Chauncey Cherry Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2009 Nov-Dec
Authors: Joseph N Mwangi; William M Gilliland; Nicole White; Craig Sykes; Amanda Poliseno; Kelly A Knudtson; Lisa Hightow-Weidman; Angela D M Kashuba; Elias P Rosen Journal: Antimicrob Agents Chemother Date: 2022-03-10 Impact factor: 5.938